Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors

PHASE2RecruitingINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

September 7, 2021

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions
Progression-free SurvivalGastrointestinal Stromal TumorNeoadjuvant
Interventions
DRUG

Imatinib

Imatinib neoadjuvant therapy

Trial Locations (1)

310003

RECRUITING

The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
collaborator

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

collaborator

Sir Run Run Shaw Hospital

OTHER

collaborator

Zhejiang Cancer Hospital

OTHER

collaborator

First Affiliated Hospital of Wenzhou Medical University

OTHER

collaborator

Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University

OTHER

collaborator

Ningbo No. 1 Hospital

OTHER

lead

First Affiliated Hospital of Zhejiang University

OTHER